The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches

D Cruceriu, O Baldasici, O Balacescu… - Cellular Oncology, 2020 - Springer
Background Breast cancer is the most prevalent cancer among women worldwide and the
fifth cause of death among all cancer patients. Breast cancer development is driven by …

Macrophages are a double-edged sword: molecular crosstalk between tumor-associated macrophages and cancer stem cells

S Luo, G Yang, P Ye, N Cao, X Chi, WH Yang, X Yan - Biomolecules, 2022 - mdpi.com
Cancer stem cells (CSCs) are a subset of highly tumorigenic cells in tumors. They have
enhanced self-renewal properties, are usually chemo-radioresistant, and can promote tumor …

Immunotherapy for chordoma and chondrosarcoma: current evidence

JI Traylor, MN Pernik, AR Plitt, M Lim, T Garzon-Muvdi - Cancers, 2021 - mdpi.com
Simple Summary Chordomas and chondrosarcomas are rare tumors that can occur within
the skull base and spinal column and are often resistant to chemotherapy and radiation …

Unraveling molecular signatures in rare bone tumors and navigating the cancer pathway landscapes for targeted therapeutics

AK Wani, A Prakash, S Sena, N Akhtar, R Singh… - Critical Reviews in …, 2024 - Elsevier
Rare cancers (RCs), which account for over 20% of cancer cases, face significant research
and treatment challenges due to their limited prevalence. This results in suboptimal …

Chordoma: to know means to recognize

EN Karele, AN Paze - Biochimica et Biophysica Acta (BBA)-Reviews on …, 2022 - Elsevier
Chordoma is a rare type of bone cancer characterized by its locally aggressive and
destructive behavior. Chordoma is located in one of the three primary regions: skull …

CMTM3 suppresses chordoma progress through EGFR/STAT3 regulated EMT and TP53 signaling pathway

W Yuan, F Wei, H Ouyang, X Ren, J Hang, X Mo… - Cancer Cell …, 2021 - Springer
Background Chordomas are rare, slow-growing and locally aggressive bone sarcomas. At
present, chordomas are difficult to manage due to their high recurrence rate, metastasis …

[HTML][HTML] LncRNA MEG8 promotes TNF-α expression by sponging miR-454-3p in bone-invasive pituitary adenomas

HB Zhu, B Li, J Guo, YZ Miao, YT Shen… - Aging (Albany …, 2021 - ncbi.nlm.nih.gov
There are few studies on the mechanism of pituitary adenoma (PA) destroying bone. The
current study aimed to investigate the role of MEG8/miR-454-3p/TNF-α in bone-invasive …

Disruption of RCAN1. 4 expression mediated by YY1/HDAC2 modulates chronic renal allograft interstitial fibrosis

J Zhang, Y Zhang, D Feng, H Zhou, Z Gui… - Cell Death …, 2023 - nature.com
Chronic allograft dysfunction (CAD) is a major factor that hinders kidney transplant survival
in the long run. Epithelial–mesenchymal transition (EMT) has been confirmed to significantly …

Prognostic molecular biomarkers in chordomas: a systematic review and identification of clinically usable biomarker panels

F Rubino, C Alvarez-Breckenridge, K Akdemir… - Frontiers in …, 2022 - frontiersin.org
Introduction and objective Despite the improvements in management and treatment of
chordomas over time, the risk of disease recurrence remains high. Consequently, there is a …

Tumor suppressor role of the complement inhibitor CSMD1 and its role in TNF-induced neuroinflammation in gliomas

EC Tuysuz, E Mourati, R Rosberg, A Moskal… - Journal of Experimental …, 2024 - Springer
Background The complement inhibitor CSMD1 acts as a tumor suppressor in various types
of solid cancers. Despite its high level of expression in the brain, its function in gliomas …